Friday, March 11, 2016 5:02:00 AM PDT | VentureDeal
San Diego, California -- Biotechnology company Aspyrian Therapeutics has raised $40 million in new venture capital equity investment, according to an SEC regulatory filing.
Aspyrian is developing novel targeted therapies for cancer treatments utilizing antibody conjugates with tumor specific activation. The company has started a phase 1 study to treat recurrent head and neck cancer conditions. Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds. A total of two investors participated in the offering. Aspyrian is still seeking $5 million in additional financing, according to the filing.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
